SUSAN G KOMEN BREAST CANCER FOUNDATION: Form 990, tax year 2020

View the entire original 990 at ProPublica ↗

Organization: SUSAN G KOMEN BREAST CANCER FOUNDATION (EIN 75-1835298)
Tax period: 2020-04-01 to 2021-03-31
Filed: 2022-01-06
IRS object ID: 202230069349300168
Schema version: 2020v4.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2022-01-06T12:59:28-06:00	ReturnTs
Tax Period End	2021-03-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	ERNST & YOUNG US LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	1901 6TH AVENUE	AddressLine1Txt
City	N BIRMINGHAM	CityNm
State Abbreviation	AL	StateAbbreviationCd
ZIP	35203	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2020-04-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	751835298	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	The Susan G Komen Breast Cancer Fdn Inc	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
In Care Of	% Ria Williams	InCareOfNm
Business Name Control	SUSA	BusinessNameControlTxt
Phone	9728551600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 Noel Road Suite 801889	AddressLine1Txt
City	Dallas	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	Paula Sue Schneider	PersonNm
Person Title	President and CEO	PersonTitleTxt
Phone	9728551600	PhoneNum
Signature	2021-11-19	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

Field	Value	IRS element (for citing)
Person First	PAULA SUE	PersonFirstNm
Person Last	SCHNEIDER	PersonLastNm

Field	Value	IRS element (for citing)
SSN	999009999	SSN

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	KATHY PITTS	PreparerPersonNm
PTIN	P01080011	PTIN
Phone	2149698000	PhoneNum

Additional Filer Information AdditionalFilerInformation

Trusted Customer TrustedCustomerGrp

Field	Value	IRS element (for citing)
Trusted Customer	3	TrustedCustomerCd

Field	Value	IRS element (for citing)
Tax	2020	TaxYr
Build TS	2022-09-23 18:48:47Z	BuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

Field	Value	IRS element (for citing)
Business Name Line1	Susan G Komen	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Principal Officer	Paula Sue Schneider	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 Noel Road Suite 801889	AddressLine1Txt
City	Dallas	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$101,605,011	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Group Exemption	7164	GroupExemptionNum
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	www.komen.org	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1982	FormationYr
Legal Domicile State	TX	LegalDomicileStateCd
Activity Or Mission	Our mission is to save lives by meeting the most critical needs in our communities and investing in break- through research to prevent and cure breast cancer.	ActivityOrMissionDesc
Voting Members Governing Body	12	VotingMembersGoverningBodyCnt
Voting Members Independent	12	VotingMembersIndependentCnt
Total Employee	329	TotalEmployeeCnt
Total Volunteers	1324	TotalVolunteersCnt
Total Gross UBI	$8,328	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$59,972,314	PYContributionsGrantsAmt
CY Contributions Grants	$50,983,746	CYContributionsGrantsAmt
PY Program Service Revenue	$11,229,901	PYProgramServiceRevenueAmt
CY Program Service Revenue	$3,259,501	CYProgramServiceRevenueAmt
PY Investment Income	$6,459,076	PYInvestmentIncomeAmt
CY Investment Income	$7,389,057	CYInvestmentIncomeAmt
PY Other Revenue	-$2,874,522	PYOtherRevenueAmt
CY Other Revenue	$26,113,354	CYOtherRevenueAmt
PY Total Revenue	$74,786,769	PYTotalRevenueAmt
CY Total Revenue	$87,745,658	CYTotalRevenueAmt
PY Grants And Similar Paid	$1,959,840	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$15,229,334	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$24,559,389	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$27,327,944	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$1,917,235	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$1,158,758	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$13,307,603	CYTotalFundraisingExpenseAmt
PY Other Expenses	$40,447,365	PYOtherExpensesAmt
CY Other Expenses	$31,051,187	CYOtherExpensesAmt
PY Total Expenses	$68,883,829	PYTotalExpensesAmt
CY Total Expenses	$74,767,223	CYTotalExpensesAmt
PY Revenues Less Expenses	$5,902,940	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	$12,978,435	CYRevenuesLessExpensesAmt
Total Assets BOY	$151,061,886	TotalAssetsBOYAmt
Total Assets EOY	$193,189,248	TotalAssetsEOYAmt
Total Liabilities BOY	$47,670,630	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$55,926,370	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$103,391,256	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$137,262,878	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	Komen's mission is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer.	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Activity	32	ActivityCd
Expense	$17,226,573	ExpenseAmt
Grant	$13,519,391	GrantAmt
Revenue	$2,917,959	RevenueAmt
Desc	GRANTS TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON THE BIOLOGY OF BREAST CANCER; NEW STRATEGIES TO TREAT, DETECT, AND PREDICT RISK OF BREAST CANCER, AND UNDERSTANDING AND ADDRESSING DISPARITIES IN OUTCOMES. SEE SCHEDULE O FOR ADDITIONAL DETAILS.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Activity	32	ActivityCd
Expense	$30,411,145	ExpenseAmt
Grant	$1,709,943	GrantAmt
Revenue	$594,769	RevenueAmt
Desc	PATIENT CARE AND ADVOCACY: PROVISION OF BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS THROUGH GRANTS TO OTHER NON-PROFIT ORGANIZATIONS, THIRD-PARTY CONTRACTS AND DIRECTLY BY KOMEN, WITH A SPECIAL EMPHASIS ON PATIENT NAVIGATION, ESPECIALLY IN COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$47,637,718	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Subject To Proxy Tax	false	SubjectToProxyTaxInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	false	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (true)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	Yes (true)	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	false	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	false	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (true)	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	false	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	Yes (true)	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	false	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	false	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	false	RelatedEntityInd
Related Organization Ctrl Ent	false	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	67	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	329	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (true)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (true)	Form990TFiledInd
Foreign Financial Account	false	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	Yes (true)	Form8282PropertyDisposedOfInd
Form8282 Filed	2	Form8282FiledCnt
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	false	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	false	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	12	GoverningBodyVotingMembersCnt
Independent Voting Member	12	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	Yes (true)	LocalChaptersInd
Policies Reference Chapters	Yes (true)	PoliciesReferenceChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AZ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	Ria Williams	PersonNm
Phone	9728551600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 Noel Road Suite 801889	AddressLine1Txt
City	Dallas	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (25 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd
Paula Schneider
President & CEO	55.0	0.0	Yes (X)	$530,086	$0	$23,471
Dana Brown
Chief Operating Officer	55.0	0.0	Yes (X)	$364,663	$0	$7,330
Christina Alford
Former SVP, DEV (END 7/20)	0.0	0.0		$251,976	$0	$6,388	Yes (X)
Catherine Olivieri
VP, HR	55.0	0.0		$226,260	$0	$18,697	Yes (X)
Victoria Wolodzko
SVP, Mission	55.0	0.0		$234,741	$0	$7,256	Yes (X)
Sarah Rosales
VP, Corporate Partnerships	55.0	0.0		$222,385	$0	$14,487		Yes (X)
Ria Williams
Chief Financial Officer	55.0	0.0	Yes (X)	$215,400	$0	$18,913
Eunice Nakamura
Gen Counsel & Corp Secretary	55.0	0.0	Yes (X)	$202,364	$0	$6,148
Srinivas Avadhanula
VP, BI Platform & Engineering	55.0	0.0		$198,146	$0	$3,309		Yes (X)
Michelle Strong
VP, Marketing Strategy	55.0	0.0		$188,440	$0	$9,300		Yes (X)
Lori Maris
SVP, Community Dev & Operation	55.0	0.0		$181,163	$0	$14,039	Yes (X)
Kimberly Sabelko
VP, Scientific Strategy & Prog	55.0	0.0		$165,638	$0	$13,938		Yes (X)
Kimberly Johnson
Sr. Director AAHEI	55.0	0.0		$162,994	$0	$1,920		Yes (X)
Peter D Brundage
Chair of the Board	1.0	0.0	Yes (X)	$0	$0	$0			Yes (X)
John O'Neill
Board Member	1.0	0.0		$0	$0	$0			Yes (X)
Christina Minnis
BOARD MEMBER	1.0	0.0		$0	$0	$0			Yes (X)
Susannah Gray
BOARD MEMBER	1.0	0.0		$0	$0	$0			Yes (X)
Jerri Johnson
BOARD MEMBER	1.0	0.0		$0	$0	$0			Yes (X)
Kwanza Jones
BOARD MEMBER	1.0	0.0		$0	$0	$0			Yes (X)
Eugene Kim
BOARD MEMBER	1.0	0.0		$0	$0	$0			Yes (X)
Kaye Ceille
BOARD MEMBER	1.0	0.0		$0	$0	$0			Yes (X)
Doug Knutson MD
Board Member	1.0	0.0		$0	$0	$0			Yes (X)
Kristin Nimsger
BOARD Member	1.0	0.0		$0	$0	$0			Yes (X)
Stephanie Stahl
BOARD Member	1.0	0.0		$0	$0	$0			Yes (X)
Ed Dandridge Beg 0620
Board Member	1.0	0.0		$0	$0	$0			Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$3,144,256	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$145,196	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	47	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	false	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
Event 360
205 N Michigan Ave	Chicago	IL	60601	Event Management	$2,377,321
RKD Group LLC
3400 Waterview Parkway Suite 250	Richardson	TX	75080	Consulting	$1,259,716
Cancer Care Inc
275 Seventh Ave 22nd Floor	New York	NY	10001	Program Services	$581,688
Charity Dynamics
6300 Bridge Point Parkway 240	Austin	TX	78730	Consulting	$404,730
Ernst Young
3712 Solutions Center	Chicago	IL	60677	ACCTING & TAX SVCS	$340,622

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	17	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$150,066	FederatedCampaignsAmt
Membership Dues	$0	MembershipDuesAmt
Fundraising	$5,296,212	FundraisingAmt
Related Organizations	$0	RelatedOrganizationsAmt
Government Grants	$0	GovernmentGrantsAmt
All Other Contributions	$45,537,468	AllOtherContributionsAmt
Noncash Contributions	$21,053	NoncashContributionsAmt
Total Contributions	$50,983,746	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

Field	Value	IRS element (for citing)
Desc	AFFILIATE PROGRAM FUNDING	Desc
Business	900099	BusinessCd
Total Revenue Column	$3,259,501	TotalRevenueColumnAmt
Related Or Exempt Func Income	$3,259,501	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$3,259,501	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,176,581	TotalRevenueColumnAmt
Exclusion	$1,176,581	ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$40,962	TotalRevenueColumnAmt
Exclusion	$40,962	ExclusionAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$19,651,333	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$13,438,857	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$6,212,476	SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$6,212,476	TotalRevenueColumnAmt
Exclusion	$6,212,476	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$40,750	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$5,296,212	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$313,023	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$272,273	TotalRevenueColumnAmt
Exclusion	-$272,273	ExclusionAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$0	GamingGrossIncomeAmt
Gaming Direct Expenses	$0	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$112,375	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$107,473	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$4,902	TotalRevenueColumnAmt
Related Or Exempt Func Income	$4,902	RelatedOrExemptFuncIncomeAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	ExclusionExclusionAmt
SHARED SERVICES	900099	$248,325	$248,325	$0	$0
OTHER INCOME	900099	$15,070	$0	$8,328	$6,742
MERGER RELATED INCOME	900099	$26,076,368	$0	$0	$26,076,368

Field	Value	IRS element (for citing)
Other Revenue Total	$26,339,763	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$87,745,658	TotalRevenueColumnAmt
Related Or Exempt Func Income	$3,512,728	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$8,328	UnrelatedBusinessRevenueAmt
Exclusion	$33,240,856	ExclusionAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part IX	Yes (X)	InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$14,528,634	TotalAmt
Program Services	$14,528,634	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$700,700	TotalAmt
Program Services	$700,700	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,039,263	TotalAmt
Program Services	$1,366,306	ProgramServicesAmt
Management And General	$305,890	ManagementAndGeneralAmt
Fundraising	$367,067	FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$21,870,270	TotalAmt
Program Services	$10,314,887	ProgramServicesAmt
Management And General	$8,513,674	ManagementAndGeneralAmt
Fundraising	$3,041,709	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$161,609	TotalAmt
Program Services	$74,915	ProgramServicesAmt
Management And General	$61,687	ManagementAndGeneralAmt
Fundraising	$25,007	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$1,830,558	TotalAmt
Program Services	$868,187	ProgramServicesAmt
Management And General	$747,887	ManagementAndGeneralAmt
Fundraising	$214,484	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$1,426,244	TotalAmt
Program Services	$700,294	ProgramServicesAmt
Management And General	$523,565	ManagementAndGeneralAmt
Fundraising	$202,385	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$194,975	TotalAmt
Program Services	$98,815	ProgramServicesAmt
Management And General	$28,893	ManagementAndGeneralAmt
Fundraising	$67,267	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$479,245	TotalAmt
Program Services	$65,285	ProgramServicesAmt
Management And General	$378,960	ManagementAndGeneralAmt
Fundraising	$35,000	FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$172,474	TotalAmt
Program Services	$172,474	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$1,158,758	TotalAmt
Fundraising	$1,158,758	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$190,951	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$190,951	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$2,940,940	TotalAmt
Program Services	$1,550,573	ProgramServicesAmt
Management And General	$341,532	ManagementAndGeneralAmt
Fundraising	$1,048,835	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$14,475,580	TotalAmt
Program Services	$8,698,743	ProgramServicesAmt
Management And General	$91,892	ManagementAndGeneralAmt
Fundraising	$5,684,945	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$1,797,179	TotalAmt
Program Services	$1,204,110	ProgramServicesAmt
Management And General	$269,577	ManagementAndGeneralAmt
Fundraising	$323,492	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$1,229,843	TotalAmt
Program Services	$719,598	ProgramServicesAmt
Management And General	$370,476	ManagementAndGeneralAmt
Fundraising	$139,769	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$20,637	TotalAmt
Program Services	$7,139	ProgramServicesAmt
Management And General	$10,893	ManagementAndGeneralAmt
Fundraising	$2,605	FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$52,454	TotalAmt
Program Services	$34,404	ProgramServicesAmt
Management And General	$8,506	ManagementAndGeneralAmt
Fundraising	$9,544	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$536,058	TotalAmt
Program Services	$290,071	ProgramServicesAmt
Management And General	$157,478	ManagementAndGeneralAmt
Fundraising	$88,509	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$229,098	TotalAmt
Program Services	$226,328	ProgramServicesAmt
Management And General	$2,770	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
Consult & Prof. Fees	$5,599,172	$4,998,057	$250,884	$350,231
Equip Rental & Maint	$971,648	$193,405	$612,003	$166,240
Event Production	$994,127	$491,281	$352,816	$150,030
Bank Fees	$438,821	$40,561	$166,534	$231,726

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$727,985	TotalAmt
Program Services	$292,951	ProgramServicesAmt
Management And General	$435,034	ManagementAndGeneralAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$74,767,223	TotalAmt
Program Services	$47,637,718	ProgramServicesAmt
Management And General	$13,821,902	ManagementAndGeneralAmt
Fundraising	$13,307,603	FundraisingAmt

Field	Value	IRS element (for citing)
Joint Costs	Yes (X)	JointCostsInd

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$32,413,462	TotalAmt
Program Services	$17,071,600	ProgramServicesAmt
Management And General	$3,699,000	ManagementAndGeneralAmt
Fundraising	$11,642,862	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$16,576,575	BOYAmt
EOY	$27,119,307	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$25,407,636	BOYAmt
EOY	$20,276,918	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$110,871	BOYAmt
EOY	$6,957	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$1,632,025	BOYAmt
EOY	$2,239,524	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$9,783,122	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$7,533,353	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$804,736	BOYAmt
EOY	$2,249,769	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$54,648,890	BOYAmt
EOY	$102,135,416	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$51,881,153	BOYAmt
EOY	$39,150,000	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$11,357	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$151,061,886	BOYAmt
EOY	$193,189,248	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$7,278,558	BOYAmt
EOY	$9,143,376	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$40,205,041	BOYAmt
EOY	$41,640,671	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$187,031	BOYAmt
EOY	$614,778	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$4,527,545	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$47,670,630	BOYAmt
EOY	$55,926,370	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$47,196,408	BOYAmt
EOY	$90,698,864	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$56,194,848	BOYAmt
EOY	$46,564,014	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$103,391,256	BOYAmt
EOY	$137,262,878	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$151,061,886	BOYAmt
EOY	$193,189,248	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	$12,978,435	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$20,186,210	NetUnrlzdGainsLossesInvstAmt
Donated Services And Use Fclts	$484,237	DonatedServicesAndUseFcltsAmt
Investment Expense	-$190,951	InvestmentExpenseAmt
Prior Period Adjustments	$0	PriorPeriodAdjustmentsAmt
Other Changes In Net Assets	$413,691	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	false	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$55,634,984	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$51,441,732	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$63,291,987	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$59,972,314	CurrentTaxYearMinus1YearAmt
Current Tax Year	$50,983,746	CurrentTaxYearAmt
Total	$281,324,763	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$55,634,984	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$51,441,732	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$63,291,987	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$59,972,314	CurrentTaxYearMinus1YearAmt
Current Tax Year	$50,983,746	CurrentTaxYearAmt
Total	$281,324,763	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$15,973,641	SubstantialContributorsTotAmt
Public Support Total170	$265,351,122	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$2,265,964	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$5,667,273	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$5,221,701	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$4,928,838	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,217,543	CurrentTaxYearAmt
Total	$19,301,319	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$0	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$0	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$0	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$0	CurrentTaxYearMinus1YearAmt
Total	$0	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$51,821	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$124,523	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$34,200	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$86,442	CurrentTaxYearMinus1YearAmt
Current Tax Year	$15,070	CurrentTaxYearAmt
Total	$312,056	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$300,938,138	TotalSupportAmt
Gross Receipts Rltd Activities	$90,056,446	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.88175	PublicSupportCY170Pct
Public Support PY170	0.81986	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Organization Belongs Afflt Grp	Yes (X)	OrganizationBelongsAffltGrpInd

Total Grassroots Lobbying TotalGrassrootsLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$38,616	FilingOrganizationsTotalAmt
Affiliated Group Total	$38,616	AffiliatedGroupTotalAmt

Total Direct Lobbying TotalDirectLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$133,858	FilingOrganizationsTotalAmt
Affiliated Group Total	$137,126	AffiliatedGroupTotalAmt

Total Lobbying Expend TotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$172,474	FilingOrganizationsTotalAmt
Affiliated Group Total	$175,742	AffiliatedGroupTotalAmt

Other Exempt Purpose Expend OtherExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$60,772,846	FilingOrganizationsTotalAmt
Affiliated Group Total	$95,547,558	AffiliatedGroupTotalAmt

Total Exempt Purpose Expend TotalExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$60,945,320	FilingOrganizationsTotalAmt
Affiliated Group Total	$95,723,300	AffiliatedGroupTotalAmt

Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$1,000,000	FilingOrganizationsTotalAmt
Affiliated Group Total	$1,000,000	AffiliatedGroupTotalAmt

Grassroots Nontaxable GrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$250,000	FilingOrganizationsTotalAmt
Affiliated Group Total	$250,000	AffiliatedGroupTotalAmt

Field	Value	IRS element (for citing)
Tot Lbbyng Grassroot Mns Non Tx		TotLbbyngGrassrootMnsNonTxGrp
Tot Lbby Expend Mns Lbbyng Non Tx		TotLbbyExpendMnsLbbyngNonTxGrp

Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$1,000,000	CurrentYearMinus3Amt
Current Year Minus2	$1,000,000	CurrentYearMinus2Amt
Current Year Minus1	$1,000,000	CurrentYearMinus1Amt
Current Year	$1,000,000	CurrentYearAmt
Total	$4,000,000	TotalAmt

Field	Value	IRS element (for citing)
Lobbying Ceiling	$6,000,000	LobbyingCeilingAmt

Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$253,525	CurrentYearMinus3Amt
Current Year Minus2	$279,269	CurrentYearMinus2Amt
Current Year Minus1	$343,462	CurrentYearMinus1Amt
Current Year	$172,474	CurrentYearAmt
Total	$1,048,730	TotalAmt

Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$250,000	CurrentYearMinus3Amt
Current Year Minus2	$250,000	CurrentYearMinus2Amt
Current Year Minus1	$250,000	CurrentYearMinus1Amt
Current Year	$250,000	CurrentYearAmt
Total	$1,000,000	TotalAmt

Field	Value	IRS element (for citing)
Grassroots Ceiling	$1,500,000	GrassrootsCeilingAmt

Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$19,478	CurrentYearMinus3Amt
Current Year Minus2	$64,115	CurrentYearMinus2Amt
Current Year Minus1	$86,368	CurrentYearMinus1Amt
Current Year	$38,616	CurrentYearAmt
Total	$208,577	TotalAmt

Field	Value	IRS element (for citing)
Media Advertisements	$0	MediaAdvertisementsAmt
Mailings Members	$0	MailingsMembersAmt
Publications Or Broadcast	$0	PublicationsOrBroadcastAmt
Grants Other Organizations	$0	GrantsOtherOrganizationsAmt
Direct Contact Legislators	$0	DirectContactLegislatorsAmt
Rallies Demonstrations	$0	RalliesDemonstrationsAmt
Other Activities	$0	OtherActivitiesAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	LOBBYING EXPENSES	FormAndLineReferenceDesc
Explanation	SCHEDULE C, PART II-A PUBLIC POLICY AND ADVOCACY INITIATIVES HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER. RECOGNIZING THE IMPORTANCE OF THIS WORK TO ACCOMPLISH ITS MISSION, KOMEN SUPPORTS LIMITED ADVOCACY/LOBBYING ACTIVITIES TO ACHIEVE LEGISLATIVE AND REGULATORY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE, AND FUND CRITICAL BREAST CANCER RESEARCH.	ExplanationTxt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amounts		ArtPublicExhibitionAmountsGrp
Held Works Art		HeldWorksArtGrp

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,337,562	BeginningYearBalanceAmt
Investment Earnings Or Losses	$10,279	InvestmentEarningsOrLossesAmt
Other Expenditures	$5,668	OtherExpendituresAmt
End Year Balance	$1,342,173	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,333,603	BeginningYearBalanceAmt
Investment Earnings Or Losses	$9,803	InvestmentEarningsOrLossesAmt
Other Expenditures	$5,844	OtherExpendituresAmt
End Year Balance	$1,337,562	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,362,090	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	-$4,016	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$24,267	OtherExpendituresAmt
Administrative Expenses	$204	AdministrativeExpensesAmt
End Year Balance	$1,333,603	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,377,855	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$10,034	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$25,799	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,362,090	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,376,069	BeginningYearBalanceAmt
Investment Earnings Or Losses	$1,786	InvestmentEarningsOrLossesAmt
Other Expenditures	$0	OtherExpendituresAmt
End Year Balance	$1,377,855	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.75000	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.24000	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.01000	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd

Land LandGrp

Field	Value	IRS element (for citing)
Book Value	$0	BookValueAmt

Field	Value	IRS element (for citing)
Buildings		BuildingsGrp

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$83,890	OtherCostOrOtherBasisAmt
Depreciation	$24,468	DepreciationAmt
Book Value	$59,422	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,884,499	OtherCostOrOtherBasisAmt
Depreciation	$1,557,619	DepreciationAmt
Book Value	$326,880	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$7,814,733	OtherCostOrOtherBasisAmt
Depreciation	$5,951,266	DepreciationAmt
Book Value	$1,863,467	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$2,249,769	TotalBookValueLandBuildingsAmt
Financial Derivatives		FinancialDerivativesGrp
Closely Held Equity Interests		CloselyHeldEquityInterestsGrp

Other Securities OtherSecuritiesGrp

Field	Value	IRS element (for citing)
Desc	Private equity fund	Desc
Book Value	$39,150,000	BookValueAmt
Method Valuation	F	MethodValuationCd

Field	Value	IRS element (for citing)
Total Book Value Securities	$39,150,000	TotalBookValueSecuritiesAmt
Federal Income Tax Liability	$0	FederalIncomeTaxLiabilityAmt
Total Liability	$0	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Intended use of endowment funds	SCHEDULE D, PART V, LINE 4 KOMEN HAS THREE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, AND A GENERAL ENDOWMENT. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, AND THE GENERAL ENDOWMENT'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES.
FIN 48 (ASC 740) FINANCIAL STATEMENT DISCLOSURE	SCHEDULE D, PART X, LINE 2 THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2021.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (12 entries)

RegionRegionTxt	OfficesOfficesCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
East Asia and the Pacific	4	Grantmaking	Research	$254,938
Europe (Including Iceland and Greenland)	1	Grantmaking	Research	$10,000
Europe (Including Iceland and Greenland)	6	Grantmaking	Research	$446,258
Europe (Including Iceland and Greenland)	1	Program services	Learning Mgmt System	$16,189
Europe (Including Iceland and Greenland)	1	Program services	Legal Services	$4,425
North America	4	Grantmaking	Research	$333,020
North America	1	Program services	IT Services	$34,390
North America	1	Program services	MISSION TOOL DEV	$3,802,203
North America	1	Program services	Event Production	$24,021
North America	1	Fundraising	Fundraising Support	$7,608
Sub-Saharan Africa	1	Grantmaking	Research	$19,514
Sub-Saharan Africa	1	Grantmaking	PATIENT CARE	$79,992

Field	Value	IRS element (for citing)
Subtotal Offices	23	SubtotalOfficesCnt
Total Office	23	TotalOfficeCnt
Subtotal Spent	$5,032,558	SubtotalSpentAmt
Total Spent	$5,032,558	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (19 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt
Sub-Saharan Africa	RESEARCH	$19,514
Europe (Including Iceland and Greenland)	Research	$10,000
East Asia and the Pacific	RESEARCH	$59,921
Europe (Including Iceland and Greenland)	RESEARCH	$51,983
Europe (Including Iceland and Greenland)	RESEARCH	$89,763
Europe (Including Iceland and Greenland)	Research	$74,685
Europe (Including Iceland and Greenland)	RESEARCH	$16,000
East Asia and the Pacific	RESEARCH	$78,710
North America	RESEARCH	$30,000
North America	Research	$88,125
Europe (Including Iceland and Greenland)	RESEARCH	$54,000
North America	Research	$80,000
Europe (Including Iceland and Greenland)	RESEARCH	$149,828
North America	Research	$59,903
Sub-Saharan Africa	PATIENT CARE	$79,992
North America	RESEARCH	$74,992
East Asia and the Pacific	Research	$21,555
East Asia and the Pacific	RESEARCH	$90,000
Europe (Including Iceland and Greenland)	PATIENT CARE	$10,000

Field	Value	IRS element (for citing)
Total501c3 Org	20	Total501c3OrgCnt
Transfer To Foreign Corp	false	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	Yes (true)	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Procedures for Monitoring Use of Grants	FormAndLineReferenceDesc
Explanation	AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, ALL GRANTEES ARE REQUIRED TO SUBMIT SCIENTIFIC PROGRESS REPORTS AND FINANCIAL REPORTS IN THE FORMAT REQUIRED BY KOMEN AND IN ACCORDANCE WITH THE SCHEDULE SET FORTH IN THE POLICIES AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV AND SCHEDULE O, Part IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.	ExplanationTxt

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
In Person Solicitations	Yes (X)	InPersonSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (5 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Gross ReceiptsGrossReceiptsAmt	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt
Event 360
55 E JACKSON BLVD SUITE 1010	CHICAGO	IL	60604	Fundraising Consultant	false	$502,231	$593,119	-$90,888
RKD GROUP LLC
3400 WATERVIEW PARKWAY SUITE 250	RICHARDSON	TX	75080	Fundraising Consultant	false	$22,648,672	$512,828	$22,135,844
BLUE STATE DIGITAL INC
41 FLATBRUSH AVENUE 8TH FL	BROOKLYN	NY	11217	Marketing Consultant	false	$0	$15,317	-$15,317
Revunami Inc
228 E 85TH ST SUITE 9C	NEW YORK	NY	10028	Marketing Consultant	false	$0	$22,124	-$22,124
TURNKEY PROMOTIONS INC
3310 ROSEDAL AVENUE	RICHMOND	VA	23230	Marketing Consultant	false	$0	$15,370	-$15,370

Field	Value	IRS element (for citing)
Total Gross Receipts	$23,150,903	TotalGrossReceiptsAmt
Total Retained By Contractors	$1,158,758	TotalRetainedByContractorsAmt
Total Net To Organization	$21,992,145	TotalNetToOrganizationAmt
Licensed States	AL	LicensedStatesCd
Licensed States	AK	LicensedStatesCd
Licensed States	AZ	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DC	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	ID	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	IN	LicensedStatesCd
Licensed States	IA	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	MT	LicensedStatesCd
Licensed States	NE	LicensedStatesCd
Licensed States	NV	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	SD	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	TX	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd
Licensed States	WY	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	3 Day Series	Event1Nm
Gross Receipts Event1	$3,155,568	GrossReceiptsEvent1Amt
Charitable Contri Event1	$3,155,568	CharitableContriEvent1Amt
Rent Facility Costs Event1	$290,887	RentFacilityCostsEvent1Amt
Other Direct Expenses Event1	$6,949	OtherDirectExpensesEvent1Amt
Event2	Race Walk	Event2Nm
Gross Receipts Event2	$1,940,335	GrossReceiptsEvent2Amt
Charitable Contri Event2	$1,902,160	CharitableContriEvent2Amt
Gross Revenue Event2	$38,175	GrossRevenueEvent2Amt
Other Direct Expenses Event2	$12,061	OtherDirectExpensesEvent2Amt
Other Events Total	12	OtherEventsTotalCnt
Gross Receipts Other Events	$241,059	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$238,484	CharitableContriOtherEventsAmt
Gross Revenue Other Events	$2,575	GrossRevenueOtherEventsAmt
Oth Direct Expnss Other Events	$3,126	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$5,336,962	GrossReceiptsTotalAmt
Charitable Contributions Tot	$5,296,212	CharitableContributionsTotAmt
Gross Revenue Total Events	$40,750	GrossRevenueTotalEventsAmt
Rent Fclty Costs Total Events	$290,887	RentFcltyCostsTotalEventsAmt
Oth Direct Expnss Total Events	$22,136	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$313,023	DirectExpenseSummaryEventsAmt
Net Income Summary	-$272,273	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE G PART I	THE MAJORITY OF FUNDRAISING CONSULTING COSTS WITHOUT CORRESPONDING GROSS RECEIPTS ARE ASSOCIATED WITH KOMEN'S AFFILIATE NETWORK FUNDRAISING EFFORTS. THE GROSS RECEIPTS ARE RETAINED BY THE AFFILIATES.
NET INCOME SUMMARY	SCHEDULE G PART II GROSS RECEIPTS ARE REDUCED BY THE AMOUNT OF CONTRIBUTIONS, PER IRS INSTRUCTIONS. THE CONTRIBUTIONS FOR FISCAL YEAR 2021 WERE $5,296,212.

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (80 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt
AFRICAN WOMENS CANCER AWARENESS ASSOC
8955 EDMONSTON ROAD	GREENBELT	MD	20770	731704355	501c3	$9,966	PATIENT CARE
ALBANY MEDICAL COLLEGE
ATTN FRANCES ALBERT	ALBANY	NY	12208	141338310	501c3	$59,976	RESEARCH
ARLINGTON FREE CLINIC
2921 11th Street South	Arlington	VA	22204	541671883	501c3	$10,000	PATIENT CARE
BAYLOR COLLEGE OF MEDICINE
ONE BAYLOR PLAZA BCM 206	Houston	TX	770303411	741613878	501c3	$570,492	RESEARCH
BAYLOR UNIVERSITY
ONE BAYLOR PLAZA BCM 206	HOUSTON	TX	770303411	741613878	501c3	$75,000	Research
BOSTON UNIVERSITY
225 BAY STATE ROAD	Boston	MA	02215	042103547	501c3	$200,000	Research
BREAST CANCER FOR WASHINGTON
4 ATLANTIC ST SW	WASHINGTON	DC	20032	455574713	501c3	$20,000	PATIENT CARE
BRIGHAM AND WOMEN'S HOSPITAL
181 LONGWOOD AVENUE 5TH FL	BOSTON	MA	02115	510197108	501c3	$99,619	Research
BURNAM INSTITUTE FOR MEDICAL RESEARCH
10901 NORTH TORREY PINES ROAD	LA JOLLA	CA	92037	510197108	501c3	$74,992	RESEARCH
COLUMBIA UNIVERSITY MEDICAL CENTER
615 WEST 131ST STREET	NEW YORK	NY	10027	135598093	501c3	$100,000	Research
DANA-FARBER CANCER INSTITUTE INC
450 BROOKLINE AVENUE BP 412	BOSTON	MA	02115	042263040	501c3	$998,440	RESEARCH
DUKE UNIVERSITY MEDICAL CENTER
324 BLACKWEEL STREET STE 1000	DURHAM	NC	27701	560532129	501c3	$23,968	RESEARCH
FOX CHASE CANCER CENTER
333 COTTMAN AVENUE	PHILADELPHIA	PA	19111	232003072	501c3	$60,000	Research
FRED HUTCHINSON CANCER RESEARCH CENTER
PO BOX 19024 MS J6-330	SEATTLE	WA	98109	563744111	501c3	$222,483	RESEARCH, PATIENT CARE
H LEE MOFFITT CANCER CENTER
12902 MAGNOLIA DRIVE	TAMPA	FL	33612	593238636	501c3	$56,787	Research
HARVARD MEDICAL SCHOOL
HOLYOKE CENTER ROOM 600	CAMBRIDGE	MA	02138	042103580	501c3	$399,000	Research
INDIANA U (INDIANAPOLIS)
PO BOX 66057	INDIANAPOLIS	IN	46266	356001673	501c3	$578,130	Research
JOHNS HOPKINS UNIVERSITY
1650 ORLEANS STREET	BALTIMORE	MD	21231	520595110	501c3	$937,500	Research
JOHN HOPKINS U
1101 EAST 33RD STREET EASTERN C220	BALTIMORE	MD	21218	520595110	501c3	$207,886	Research, PATIENT CARE
KINGMAN REGIONAL MEDICAL CENTER
3269 STOCKTON HILL RD	KINGMAN	AZ	86409	742388735	501c3	$28,907	EDUCATION
LELAND STANFORD JR UNIVERSITY
PO BOX 44253	SAN FRANCISCO	CA	94144	941156365	501c3	$200,000	Research
LOYOLA UNIVERSITY CHICAGO
820 N MICHIGAN AVENUE	CHICAGO	IL	60611	361408475	501c3	$41,971	Research
MARY'S CTR FOR MATERNAL & CHILD CARE
2333 ONTARIO ROAD NW	WASHINTON	DC	20009	521594116	501c3	$20,002	PATIENT CARE
MAYO CLINIC ROCHESTER
200 FIRST STREET SW PO BOX 4008	ROCHESTER	MN	55903	416011702	501c3	$80,000	RESEARCH
MEDICAL COLLEGE OF WISCONSIN
8701 W WATERTOWN PLANK RD	MILWAUKEE	WI	53226	390806261	501c3	$27,828	Research
MEMORIAL SLOAN-KETTERING CANCER CENTER
633 THIRD AVENUE 28TH FL	NEW YORK	NY	10017	131924236	501c3	$275,000	RESEARCH
METHODIST HOSPITAL RESEARCH INSTITUTE
6565 FANNIN STREET	HOUSTON	TX	77030	870721923	501c3	$24,000	Research
MOUNT SINAI SCHOOL OF MEDICINE
ONE GUSTAVE L LEVY PLACE	NEW YORK	NY	10029	136171197	501c3	$150,000	Research
MOUNTAIN PARK HEALTH CTR
3003 N 3RD STREET SUITE 1600	PHOENIX	AZ	85012	860498020	501c3	$16,668	PATIENT CARE
NEIGHBORHOOD HEALTH
2 EAST GLEBE ROAD	ALEXANDRIA	VA	22305	541849891	501c3	$7,258	PATIENT CARE
NORTH COUNTRY HEALTHCARE INC
2920 N 4TH STREET	FLAGSTAFF	AZ	86004	860663432	501c3	$33,333	PATIENT CARE
NORTHWESTERN UNIVERSITY-CHICAGO
633 CLARK	EVANSTON	IL	60208	362167817	501c3	$55,140	RESEARCH
NUEVA VIDA INC
2000 P STREET NW SUITE 300	WASHINGTON	DC	20036	541943145	501c3	$20,000	PATIENT CARE
OREGON HEALTH & SCIENCE UNIVERSITY
0690 SW BANCROFT STREET	PORTLAND	OR	97239	752668014	501c3	$24,684	Research
PRINCETON UNIVERSITY
701 CARNEGIE CENTER	PRINCETON	NJ	08540	210634501	501c3	$224,000	RESEARCH
PROVIDENCE PORTLAND MEDICAL CENTER
PO BOX 13993	PORTLAND	OR	97213	930386906	501c3	$75,000	RESEARCH
PURDUE UNIVERSITY
23510 NETWORK PLACE	CHICAGO	IL	60673	356002041	501c3	$27,024	RESEARCH
ROSWELL PARK ALLIANCE FOUNDATION
ELM CARLTON STREETS	BUFFALO	NY	14263	161391608	501c3	$240,000	RESEARCH
STANFORD UNIVERSITY
PO BOX 44253	SAN FRANCISCO	CA	94144	941156365	501c3	$248,000	Research
STEVENS INSTITUTE OF TECHNOLOGY
1 CASTLE POINT TERRACE	HOBOKEN	NJ	07030	221487354	501c3	$23,129	Research
THE OHIO STATE UNIVERSITY COLLEGE
700 CHILDRENS DRIVE	COLUMBUS	OH	43205	316025986	501c3	$56,945	RESEARCH
THE SALK INSTITUTE
10010 NORTH TORREY PINES ROAD	LA JOLLA	CA	92037	376000511	501c3	$104,772	RESEARCH
THE UNIVERSITY OF TEXAS AT AUSTIN
300 W DEAN KEETON A0900 BMC 2302	AUSTIN	TX	78712	746000203	501c3	$150,000	RESEARCH
THE UNIVERSITY OF TOLEDO
2801 W BANCROFT STREET MS 944	TOLEDO	OH	43606	346401483	501c3	$89,787	RESEARCH
THE WISTAR INSTITUTE
3601 SPRUCE STREET	PHILADELPHIA	PA	19104	236434390	501c3	$135,000	RESEARCH
TULANE UNIVERSITY HEALTH SCIENCES CENTER
800 E COMMERCE	HARAHAN	LA	70023	720423889	501c3	$48,000	RESEARCH
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
104 AIRPORT DRIVE SUITE 2200 CB	CHAPEL HILL	NC	27599	566001393	501c3	$797,399	Research, PATIENT CARE
UNIVERSITY OF TEXAS MD ANDERSON CANCER CTR
PO BOX 4390	HOUSTON	TX	77210	746001118	501c3	$48,436	Research
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO
3333 CALIFORNIA ST SUITE 315	SAN FRANCISCO	CA	94118	946036493	501c3	$100,000	Research
UNIVERSITY OF CALIFORNIA-BERKLEY
2195 HEARST AVENUE ROOM 130	BERKLEY	CA	94720	956006143	501c3	$24,888	RESEARCH
UNIVERSITY OF CALIFORNIA-LOS ANGELES
10920 WILSHIRE BOULEVARD SUITE 107	LOS ANGELES	CA	90024	956006143	501c3	$56,000	Research
UNIVERSITY OF CALIFORNIA-LOS ANGELES
BOX 951432 1125 MURPHY HALL	LOS ANGELES	CA	90095	956006143	501c3	$60,000	RESEARCH
UNIVERSITY OF COLORADO DENVER
13001 E 17TH PLACE	AURORA	CO	80045	846002597	501c3	$23,449	Research
UNIVERSITY OF DELAWARE
30 LOVETT AVENUE	NEWARK	DE	19716	516000279	501c3	$59,962	RESEARCH
UNIVERSITY OF ILLINOIS AT CHICAGO
809 S MARSHFIELD AVENUE MC 551	CHICAGO	IL	60608	376000511	501c3	$35,999	RESEARCH
UNIVERSITY OF KANSAS CENTER FOR RESEARCH
2385 IRVING HILL ROAD	LAWRENCE	KS	66045	480680117	501c3	$90,000	Research
UNIVERSITY OF KANSAS MEDICAL CENTER
3901 RAINBOW BOULEVARD MSN 1039	KANSAS CITY	KS	66160	481108830	501c3	$91,774	Research
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
500 SOUTH LIMESTONE 109 KINKEAD HAL	LEXINGTON	KY	40526	616033693	501c3	$57,353	RESEARCH
UNIVERSITY OF MICHIGAN
WOLVERINE TOWER	ANN ARBOR	MI	48109	386006309	501c3	$175,453	Research
UNIVERSITY OF NOTRE DAME DU LAC
836A GRACE HALL	NOTRE DAME	IN	46556	350868188	501c3	$90,000	Research
UNIVERSITY OF PENNSYLVANIA
3451 WALNUT STREET P-211 FRANKLIN	PHILADELPHIA	PA	19104	231352685	501c3	$373,937	Research
UNIVERSITY OF PITTSBURGH
123 UNIVERSITY PLACE SUITE B21	PITTSBURGH	PA	15213	250966691	501c3	$12,411	RESEARCH
UNIVERSITY OF PITTSBURGH
3100 CATHEDRAL LEARNING	PITTSBURGH	PA	15260	250965591	501c3	$283,618	Research
UNIVERSITY OF SOUTHERN CALIFORNIA
UNIVERSITY GARDENS BLDG	LOS ANGELES	CA	90089	951642394	501c3	$14,963	Research
UNIVERSITY OF UTAH
201 SOUTH PRESIDENTS CIRCLE ROOM 4	SALT LAKE CITY	UT	84112	876000525	501c3	$275,000	RESEARCH
UNIVERSITY OF VIRGINA AT SCHOOL OF MEDICINE
PO BOX 400195	CHARLOTTESVILLE	VA	22904	546001796	501c3	$59,661	RESEARCH
UNIVERSITY OF WASHINGTON
3917 UNIVERSITY WAY NE	SEATTLE	WA	98105	396006492	501c3	$70,000	RESEARCH
UT HSC - SAN ANTONIO
7703 FLOYD CURL DRIVE	SAN ANTONIO	TX	77229	741586031	501c3	$190,000	Research
UT SOUTHWESTERN MEDICAL CENTER
PO BOX 841753	DALLAS	TX	75284	746000203	501c3	$36,000	RESEARCH
UTAH CANCER CENTER CONTROL PROGRAM
PO BOX 144620	SALT LAKE CITY	UT	84114	876000545	501c3	$129,963	PATIENT CARE
UT MD ANDERSON CANCER CENTER
1515 HOLCOME BOULEVARD UNIT 1644	HOUSTON	TX	77030	746001118	501c3	$369,485	RESEARCH
VALLEYWISE HEALTH FOUNDATION
2901 E CAMELBACK RD STE 202	PHOENIX	AZ	85016	860777567	501c3	$16,667	PATIENT CARE
VANDERBILT UNIVERSITY MEDICAL CENTER
1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	620476822	501c3	$518,338	RESEARCH
VERMONT CANCER CTR UVM COLLEGE OF MEDICINE
85 SOUTH PROSPECT STREET	BURLINGTON	VT	05405	030179440	501c3	$60,000	RESEARCH
VIRGINIA COMMONWEALTH UNIVERSITY
800 E LEIGH ST SUITE 3100	RICHMOND	VA	23284	546001758	501c3	$75,000	RESEARCH
WAYNE STATE UNIVERSITY
4100 JOHN R PRENTIS CENTER	DETROIT	MI	48201	366028429	501c3	$24,000	Research
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
1300 YORK AVENUE	NEW YORK	NY	10061	131623978	501c3	$24,000	RESEARCH
WESLEY COMMUNITY CENTER
1300 S 10TH STREET	PHOENIX	AZ	85034	860133770	501c3	$29,663	PATIENT CARE
WHITMAN-WALKER CLINIC
1701 14TH STREET NW	WASHINGTON	DC	20009	521122122	501c3	$96,633	PATIENT CARE
YALE UNIVERSITY
2 WHITNEY AVENUE	NEW HAVEN	CT	06510	060646973	501c3	$300,000	Research

Field	Value	IRS element (for citing)
Total501c3 Org	77	Total501c3OrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (2 entries)

Grant TypeGrantTypeTxt	RecipientRecipientCnt	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Valuation Method UsedValuationMethodUsedDesc
Treatment Assistance	2239	$671,700	$0	FMV
Treatment Assistance	58	$29,000	$0	FMV

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Procedures for monitoring the use of grants	FormAndLineReferenceDesc
Explanation	Schedule I, Part 1 Line 2 SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED THROUGHOUT THE GRANT TERM BY A PH.D. OR MASTERS-LEVEL RESEARCH GRANT MANAGER. FOR COMMUNITY HEALTH AND EDUCATION GRANTS, PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED OR SUPERVISED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANTS MANAGERS. AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. SEE SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	Yes (true)	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	false	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	false	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (13 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Paula Schneider
President & CEO	$525,462	$0	$0	$0	$4,624	$0	$7,718	$0	$15,753	$0	$553,557	$0	$0	$0
Dana Brown
Chief Operating Officer	$361,281	$0	$0	$0	$3,382	$0	$4,800	$0	$2,530	$0	$371,993	$0	$0	$0
Ria Williams
Chief Financial Officer	$213,621	$0	$0	$0	$1,779	$0	$4,469	$0	$14,444	$0	$234,313	$0	$0	$0
Eunice Nakamura
Gen Counsel & Corp Secretary	$200,874	$0	$0	$0	$1,490	$0	$0	$0	$6,148	$0	$208,512	$0	$0	$0
Catherine Olivieri
VP, HR	$222,878	$0	$0	$0	$3,382	$0	$4,231	$0	$14,466	$0	$244,957	$0	$0	$0
Victoria Wolodzko
SVP, Mission	$232,269	$0	$0	$0	$2,472	$0	$4,379	$0	$2,877	$0	$241,997	$0	$0	$0
Lori Maris
SVP, Community Dev & Operation	$179,047	$0	$0	$0	$2,116	$0	$3,708	$0	$10,331	$0	$195,202	$0	$0	$0
Sarah Rosales
VP, Corporate Partnerships	$206,753	$0	$14,350	$0	$1,282	$0	$0	$0	$14,487	$0	$236,872	$0	$0	$0
Srinivas Avadhanula
VP, BI Platform & Engineering	$196,848	$0	$0	$0	$1,298	$0	$0	$0	$3,309	$0	$201,455	$0	$0	$0
Michelle Strong
VP, Marketing Strategy	$187,037	$0	$0	$0	$1,403	$0	$3,692	$0	$5,608	$0	$197,740	$0	$0	$0
Kimberly Sabelko
VP, Scientific Strategy & Prog	$163,630	$0	$0	$0	$2,008	$0	$3,323	$0	$10,615	$0	$179,576	$0	$0	$0
Kimberly Johnson
Sr. Director AAHEI	$160,704	$0	$0	$0	$2,290	$0	$0	$0	$1,920	$0	$164,914	$0	$0	$0
Christina Alford
Former SVP, DEV (END 7/20)	$192,457	$0	$0	$0	$59,519	$0	$5,499	$0	$889	$0	$258,364	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	FORM 990, SCHEDULE J, PART I, LINE 4A	FormAndLineReferenceDesc
Explanation	SEVERANCE PAYMENT CHRISTINA ALFORD RECEIVED SEVERANCE OF $58,424.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (11 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART 1, LINE 6	VOLUNTEERS VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE MORE THAN PINK WALKS, RACE FOR THE CURE RUNS, AND THE SUSAN G. KOMEN 3 DAY SERIES.
FORM 990, PART III	PROGRAM SERVICE ACCOMPLISHMENTS Susan G. Komen's mission is to save lives from breast cancer, by finding breakthroughs to prevent, detect, treat, and cure breast cancer, and by meeting most critical needs in communities to ensure everyone gets the breast cancer care they need when they need it. Komen takes a 360 degree approach to fight breast cancer through . RESEARCH, to drive breakthroughs that will bring us new knowledge and advances in care for all, . COMMUNITY HEALTH, to empower people with trustworthy information and support people in their breast health journey through direct services, community programs and health systems change. . and PUBLIC POLICY, where we advocate for policies to create systemic and lasting changes that will fund and facilitate research AND alleviate the burden on patients and protect access to affordable, high-quality health care for all. Komen is a leading global breast cancer organization, having funded more breast cancer research than any other nonprofit outside of the U.S. government while providing real time help to those facing the disease. Since its founding in 1982, Komen has funded over $1.1 billion in breast cancer research in more than 2700 grants and 500 clinical trials conducted by thousands of the world's best and brightest researchers across the US and around the world. Komen has also provided over $2.3 billion in funding for patient navigation, screening, diagnosis, treatment, education , advocacy, and psychosocial support programs serving millions of people in more than 60 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life. With this investment, Komen is supporting laboratory research, translational studies, and clinical trials that are paving the road with scientific discoveries that are: - unravelling the biology of breast cancer, - leading to the development of new breast cancer drugs, - development of new technologies and tests, and - new interventions that are changing the standard of breast cancer care and improving the delivery of that care. Our goal is to advance personalized medicine and improve health outcomes for everyone. Komen has had more than 680 research discoveries since we started tracking them in 2016 that are moving us closer to that goal. Nearly two-thirds of these discoveries focus on our research priorities of conquering metastatic and aggressive breast cancers and eliminating breast cancer disparities. They include such things as new biomarkers, new drug targets, new treatments, and new healthcare delivery tools in paving this road with scientific discoveries, we're also paving it with hope. The hope that new ways to detect, diagnose, treat, prevent - and ultimately cure - breast cancer are around the corner. There when people with breast cancer need them to allow them to live longer, with improved quality of life. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, AND DEVELOPING NEW APPROACHES TO ADDRESS DISPARITIES IN BREAST CANCER OUTCOMES, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS, TECHNOLOGIES AND INTERVENTIONS. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 46 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. THIS YEAR WE ANNOUNCED THE NEW CLASS OF SIX ESTEEMED BREAST CANCER RESEARCHERS AND THREE NEW PATIENT ADVOCATES TO THE KOMEN SCHOLARS. THESE WOMEN AND MEN JOIN AN EXCLUSIVE GROUP OF BREAST CANCER RESEARCHERS, CLINICIANS AND ADVOCATES WHO HELP GUIDE THE ORGANIZATION'S WORK TO SAVE LIVES AND END BREAST CANCER. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY21, KOMEN AWARDED 30 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, IN THE UNITED STATES, CANADA, AND ZIMBABWE. CAREER CATALYST RESEARCH GRANTS SUPPORT EARLY CAREER INVESTIGATORS CONDUCTING OUTSTANDING RESEARCH THAT WILL USE LIQUID BIOPSY TECHNOLOGY TO IMPROVE THE TREATMENT AND EARLY DETECTION OF METASTATIC BREAST CANCER. LEADERSHIP GRANTS SUPPORT KOMEN SCHOLARS PURSUING INNOVATIVE RESEARCH PROJECTS WHICH WILL IMPROVE THE UNDERSTANDING, DETECTION, TREATMENT OR PREVENTION OF BREAST CANCER, WITH A FOCUS ON CONQUERING METASTATIC BREAST CANCER AND ELIMINATING BREAST CANCER DISPARITIES. THE 30 RESEARCH GRANTS AWARDED IN FY21 ARE: CAREER CATALYST RESEARCH GRANTS: HEATHER ANNE PARSONS, M.D., M.P.H., OF DANA-FARBER CANCER INSTITUTE, HAS DEVELOPED AN ULTRASENSITIVE BLOOD TEST THAT CAN DETECT CIRCULATING TUMOR DNA (CTDNA) AND TRACK PATIENT-SPECIFIC TUMOR MUTATIONS. HER2-POSITIVE METASTATIC BREAST CANCER (MBC) IS CURRENTLY CONSIDERED A TREATABLE, BUT NOT CURABLE, DISEASE. DR. PARSONS WILL USE HER NOVEL BLOOD TEST TO BETTER REFINE TREATMENT FOR PATIENTS WITH HER2-POSITIVE MBC. THUY NGO, PH.D., OF THE OREGON HEALTH & SCIENCE UNIVERSITY, WILL USE CELL FREE RNA (CFRNA) COLLECTED FROM LIQUID BIOPSY BLOOD DRAWS IN PATIENTS WITH METASTATIC BREAST CANCER AS A NEW WAY TO MONITOR IF A TREATMENT IS SUCCESSFUL FOR A PATIENT. THIS METHOD PROVIDES THE OPPORTUNITY TO GAIN A DEEPER UNDERSTANDING OF THE BEHAVIOR AND CHARACTERISTICS OF THE METASTATIC TUMOR AND TO MONITOR CHANGES IN METASTATIC LESIONS AND RESPONSES TO TREATMENT. ANA ELISA LOHMANN, M.D., PH.D., OF THE UNIVERSITY OF WESTERN ONTARIO, WILL USE LIQUID BIOPSY TO FIND PATIENT SAMPLES THAT CONTAIN CIRCULATING TUMOR DNA (CTDNA), CIRCULATING TUMOR CELLS (CTCS), OR METABOLIC MARKERS, I.E. INSULIN OR LEPTIN, THAT CORRESPOND TO TREATMENT SUCCESS AND PROGNOSIS FROM THE ONGOING MA.32 CLINICAL TRIAL. THE GOAL OF THIS PROJECT IS TO IDENTIFY HOW LIQUID BIOPSIES CAN FIND BIOMARKERS TO PREDICT WHICH HORMONE RECEPTOR-POSITIVE BREAST CANCER PATIENTS ARE AT A HIGHER RISK FOR DISEASE RECURRENCE. DANIEL STOVER, M.D., OF THE OHIO STATE UNIVERSITY, WILL COMBINE CUTTING EDGE LIQUID BIOPSY WITH IMAGING TECHNIQUES TO MONITOR DISEASE AND TREATMENT RESPONSE IN ER+/HER2-NEGATIVE BREAST CANCER PATIENTS WITH BONE METASTASES. STANDARD IMAGING OF BONE METASTASES IS NOT ONLY INACCURATE BUT CAN ALSO CREATE ANXIETY FOR INDIVIDUALS WITH BONE METASTASES. DR. STOVER WILL MONITOR CIRCULATING TUMOR DNA (CTDNA) IN COMBINATION WITH IMAGING TO PROVIDE SUPERIOR DETECTION AND MONITORING OF BONE METASTASES FOR PATIENTS WITH METASTATIC BREAST CANCER. RAYMOND MOELLERING, PH.D., OF THE UNIVERSITY OF CHICAGO, WILL USE CUTTING EDGE TECHNOLOGY TO MEASURE THE ACTIVITY OF PROTEINS INVOLVED IN BREAST CANCER FROM TUMOR CELLS FOUND CIRCULATING IN THE BLOOD. BY TAKING BLOOD, A LIQUID BIOPSY, AND USING TOOLS HE DEVELOPED, DR. MOELLERING CAN DETECT AND QUANTIFY THESE BIOMARKERS TO PROVIDE PRECISION DIAGNOSTICS AND IMPROVE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH METASTATIC DISEASE. DAVID CESCON, PH.D., OF UNIVERSITY HEALTH NETWORK, WILL USE CIRCULATING TUMOR DNA (CTDNA) COLLECTED FROM A NATIONAL CLINICAL TRIAL TO IDENTIFY BIOMARKERS IN PATIENTS WITH ALTERATIONS THAT INFLUENCE TREATMENT, I.E. PATIENTS WHERE CDK4/6 INHIBITORS MAY NOT BE AS EFFECTIVE. DR. CESCON HOPES HIS STUDIES LEAD TO PROMISING THERAPIES WITH THE POTENTIAL TO DELIVER FURTHER IMPROVEMENTS IN METASTATIC BREAST CANCER SURVIVAL, THROUGH AN INTEGRATED PROGRAM OF CLINICAL AND BENCH SCIENCE. MANOJ MENON, M.D., OF THE FRED HUTCHINSON CANCER RESEARCH CENTER, WILL STUDY THE USE OF LIQUID BIOPSY AS A MEANS FOR ACCURATE DIAGNOSIS. IN COLLABORATION WITH UGANDA CANCER INSTITUTE, DR. MENON WILL TEST WHETHER USING LIQUID BIOPSIES IS AN EFFECTIVE TOOL IN DIAGNOSIS AND MONITORING OF PATIENTS IN RESOURCE POOR AREAS WHERE ACCESS TO PATHOLOGY AND IMAGING RESOURCES ARE LIMITED. USING THIS TYPE OF TESTING, EARLY DIAGNOSIS AND TREATMENT CAN BE ACHIEVED AND HEALTH DISPARITIES CAN BE DECREASED.
LEADERSHIP GRANTS:	JENNIFER PIETENPOL, PH.D., OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL USE PATIENT SAMPLES FROM A CLINICAL TRIAL IN COMBINATION WITH PRE-CLINICAL MODELS TO BETTER UNDERSTAND HOW METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) CAN BE TARGETED AND TREATED BY A COMBINATION OF CHEMOTHERAPIES AND IMMUNOTHERAPY. THE GOAL OF THIS PROJECT IS TO UNCOVER NEW, SUBTYPE-SPECIFIC THERAPY COMBINATIONS TO PERSONALIZE TREATMENTS FOR PATIENTS WITH TNBC. BEN HO PARK, M.D., PH.D., OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL USE PRECLINICAL MODELS TO VALIDATE AND TEST HOW A MUTATED PROTEIN, SF3B1, CAN SERVE AS A TARGET FOR BREAST CANCER IMMUNOTHERAPY. THE GOAL OF THIS PROJECT IS TO DEVELOP AND PILOT A NEW PRECISION THERAPY OPTION FOR BREAST CANCER PATIENTS. ELIZABETH MORRIS, M.D., OF THE UNIVERSITY OF CALIFORNIA DAVIS, WILL CREATE A DATABASE OF PATIENT MOLECULAR DATA, GENOMIC DATA, IMAGING, AND CLINICAL OUTCOMES TO DEVELOP AN ARTIFICIAL INTELLIGENCE (AI) MODEL OF BREAST CANCER RISK PREDICTION. THE GOAL OF THIS PROJECT IS TO DEVELOP AN AI TOOL THAT CAN BETTER PREDICT BREAST CANCER RISK TO ULTIMATELY CREATE PERSONALIZED BREAST CANCER RISK PREDICTION MODELS. ABENAA BREWSTER, M.D., OF THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER, WILL ANALYZE PAIRED LIQUID BIOPSY AND TUMOR SAMPLES COLLECTED FROM PATIENTS AT MAMMOGRAPHY SCREENINGS TO IDENTIFY BIOMARKERS AND IMMUNE CHANGES INDICATIVE OF EARLY BREAST CANCER. THIS PROJECT WILL IDENTIFY AND TEST A BIOMARKER PANEL THAT CAN BE USED, IN CONJUNCTION WITH CLINICAL MAMMOGRAPHY DATA, TO DETECT PROTEIN AND IMMUNE CHANGES ASSOCIATED WITH THE EARLY DEVELOPMENT OF BREAST CANCER. THE GOAL OF THIS PROJECT IS TO DEVELOP A LOWLY INVASIVE BIOMARKER PANEL THAT CAN IDENTIFY EARLY HORMONE-RECEPTOR POSITIVE BREAST CANCERS. SHARON GIORDANO, M.D., M.P.H., OF THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER, WILL EVALUATE BOTH THE PHYSICAL AND FINANCIAL TOXICITIES ASSOCIATED WITH BREAST CANCER TREATMENT. THIS PROJECT WILL ALSO EXAMINE WHETHER BREAST CANCER TREATMENT(S) IS ASSOCIATED WITH WORSE OUTCOMES FOR BREAST CANCER PATIENTS WITH COVID-19 AND THE ROLE RACIAL DISPARITIES PLAY IN THESE OUTCOMES. THE GOAL OF THIS PROJECT IS TO IDENTIFY AND ULTIMATELY PREVENT UNNECESSARY TOXICITIES TO BREAST CANCER PATIENTS TO IMPROVE PATIENT OUTCOMES. OLUFUNMILAYO OLOPADE, M.D., OF THE UNIVERSITY OF CHICAGO, WILL COLLECT AND EXAMINE PATIENT SAMPLES FROM NIGERIAN WOMEN WITH BREAST CANCER TO IDENTIFY GENETIC AND IMMUNOLOGICAL FACTORS WHICH CONTRIBUTE TO BREAST CANCER PROGRESSION AND OUTCOMES IN WOMEN OF AFRICAN ANCESTRY. THE GOAL OF THIS PROJECT IS TO BETTER UNDERSTAND THE BIOLOGICAL BASIS OF DISPARITIES IN BREAST CANCER OUTCOMES AND IDENTIFY POSSIBLE CLINICAL TARGETS IN WOMEN OF AFRICAN ANCESTRY. ELIZABETH MITTENDORF, M.D., PH.D., OF DANA-FARBER CANCER INSTITUTE, WILL ANALYZE PATIENT SAMPLES FROM TWO DIFFERENT HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER CLINICAL TRIALS, BEFORE AND AFTER TREATMENT, TO BETTER UNDERSTAND HOW THERAPIES IMPACT THE IMMUNE SYSTEM OF BOTH THE TUMOR AND THE AREA AROUND THE TUMOR. SINCE HR+ BREAST CANCER DOES NOT RESPOND TO EXISTING IMMUNOTHERAPIES BUT COMPRISES 70% OF BREAST CANCER DIAGNOSES, THIS PROJECT SEEKS TO IDENTIFY NEW WAYS TO ENHANCE THE RESPONSE OF HR+ BREAST CANCER TO IMMUNOTHERAPY. JENNIFER LIGIBEL, M.D., OF DANA-FARBER CANCER INSTITUTE, AIMS TO TEST WHETHER WEIGHT LOSS THROUGH DIET AND EXERCISE CAN REDUCE THE RISK OF BREAST CANCER RECURRENCE IN OVERWEIGHT OR OBESE WOMEN WITH STAGE II OR III BREAST CANCER. SHE WILL CONDUCT A 5-YEAR FOLLOW-UP AND COLLECT BLOOD SAMPLES FROM TRIAL PARTICIPANTS TO ASSESS THE LONG-TERM IMPACT OF WEIGHT LOSS ON BREAST CANCER RECURRENCE AND DEVELOPING CO-MORBIDITIES. THE GOAL OF THIS STUDY IS TO DETERMINE WHETHER WEIGHT LOSS PROGRAMS SHOULD BECOME A STANDARD PART OF BREAST CANCER CARE. KEITH KNUTSON, PH.D., OF MAYO CLINIC JACKSONVILLE, AIMS TO BETTER UNDERSTAND THE ROLE OF A PROTEIN CALLED ADRENOMEDULLIN (ADM) IN THE DEVELOPMENT OF DRUG RESISTANCE IN HER2+ BREAST CANCER. USING PRE-CLINICAL MODELS, HE WILL DETERMINE HOW ADM AFFECTS HER2+ BREAST CANCER CELLS AND CONTRIBUTES TO RESISTANCE TO HER2-TARGETED THERAPIES. THE GOAL OF THIS STUDY IS TO DETERMINE IF ADM-TARGETED THERAPIES CAN BE COMBINED WITH HER2-TARGETED THERAPIES TO PREVENT BREAST CANCER RECURRENCE AND METASTATIC PROGRESSION. RESHMA JAGSI, M.D., D.PHIL., OF THE UNIVERSITY OF MICHIGAN, WILL CONDUCT STUDIES USING SEVERAL ONGOING CLINICAL TRIALS TO UNDERSTAND HOW RADIATION THERAPY, IN COMBINATION WITH DRUG TREATMENT OR SURGERY, CAN BE PERSONALIZED TO OPTIMIZE PATIENT RESPONSE TO TREATMENT. TREATMENT-RELATED PHYSICAL AND FINANCIAL TOXICITY IN AFRICAN AMERICAN BREAST CANCER PATIENTS WILL ALSO BE EVALUATED. THE GOAL IS TO PERSONALIZE RADIATION THERAPY SO THAT BREAST CANCER OUTCOMES, TREATMENT EXPERIENCE, AND QUALITY OF LIFE CAN BE IMPROVED FOR INDIVIDUALS FROM ALL RACIAL BACKGROUNDS. DONALD MCDONNELL, PH.D., OF DUKE UNIVERSITY, WILL ASSESS THE EFFECTIVENESS OF TARGETING THE PROTEINS AGR2 AND LYPD3 AS A NEW POTENTIAL COMBINATION THERAPY FOR METASTATIC ESTROGEN RECEPTOR (ER)-POSITIVE BREAST CANCER. DR. MCDONNELL'S GOAL IS TO FIND NEW THERAPEUTIC TARGETS FOR PATIENTS WITH ER-POSITIVE METASTATIC BREAST CANCERS THAT ARE RESISTANT TO ENDOCRINE THERAPY. LEADERSHIP GRANTS - NEW KOMEN SCHOLARS: LISA COUSSENS, PH.D., OF OREGON HEALTH & SCIENCE UNIVERSITY, WILL DETERMINE HOW TO SPECIFICALLY IDENTIFY AND ACTIVATE THE T RESIDENT MEMORY CELLS, A COMPONENT OF THE IMMUNE SYSTEM, WHICH CAN ATTACK BREAST TUMORS. DR. COUSSENS WILL USE PRE-CLINICAL MODELS AND CLINICALLY AVAILABLE DRUGS TO DETERMINE HOW T RESIDENT MEMORY CELLS RESPOND TO THERAPY AND DEVELOP A "SIGNATURE" TO HELP PREDICT HOW A PATIENT WILL RESPOND TO IMMUNOTHERAPY. THE GOAL OF THIS STUDY IS TO IDENTIFY HOW TO USE T CELLS TO CREATE A LONG-TERM ANTI-TUMOR "MEMORY" AGAINST BREAST CANCER AND IMPROVE PATIENT RESPONSES TO THERAPY. NIKHIL WAGLE, M.D., OF THE DANA-FARBER CANCER INSTITUTE, WILL COLLECT SAMPLES FROM OVER 3,700 PATIENTS WITH METASTATIC BREAST CANCER TO EVALUATE THE GENOMIC SIGNATURES ASSOCIATED WITH RESPONSE OR RESISTANCE TO TREATMENT. BY UNDERSTANDING THE FACTORS WHICH CONTRIBUTE TO TREATMENT RESISTANCE, DR. WAGLE HOPES TO IDENTIFY BETTER STRATEGIES TO PAIR TREATMENTS WITH METASTATIC BREAST CANCER PATIENTS OR IDENTIFY NEW THERAPEUTIC TARGETS. MELISSA TROESTER, PH.D., M.P.H., OF THE UNIVERSITY OF NORTH CAROLINA, WILL USE TUMOR AND DNA SAMPLES FROM THE CAROLINA BREAST CANCER STUDY TO EVALUATE HOW THE GENETIC AND IMMUNE COMPOSITION OF TUMORS DIFFERS BETWEEN AFRICAN AMERICAN AND WHITE WOMEN AND HOW THESE DIFFERENCES IMPACT BREAST CANCER OUTCOMES. THE GOAL OF THIS PROJECT IS TO BETTER UNDERSTAND HOW VARIATION WITHIN THE TUMORS OF AFRICAN AMERICAN WOMEN CONTRIBUTES TO RACIAL DISPARITIES IN BREAST CANCER OUTCOMES AND RECURRENCE. CHRISTINA CURTIS, PH.D., OF STANFORD UNIVERSITY, WILL USE BIG DATA AND COMPUTATIONAL BIOLOGY TECHNIQUES TO EVALUATE HIGH-RISK ER+/HER2-NEGATIVE BREAST CANCER PATIENT SAMPLES FOR THEIR RESPONSE TO TREATMENT AND RISK OF RELAPSE OR RECURRENCE. THE GOAL OF THIS PROJECT IS TO PREDICT WHICH PATIENTS HAVE A HIGHER RISK OF BREAST CANCER PROGRESSION AND RECURRENCE TO HELP CREATE PERSONALIZED RISK AND TREATMENT RESPONSE MODELS. RULLA TAMIMI, SC.D., M.S., OF JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL, WILL USE PATIENT SAMPLES AND BREAST CANCER OUTCOME DATA FROM THE NURSE'S HEALTH STUDY AND ONGOING DIETARY INTERVENTION STUDIES TO BETTER UNDERSTAND THE IMPACT INSULIN-SUPPRESSING DIETS HAVE ON BREAST CANCER RISK, RESPONSE TO TREATMENT, AND OVERALL SURVIVAL. THE GOAL OF THIS STUDY IS TO DETERMINE IF INSULIN-SUPPRESSING DIETS, SUCH AS LOW CARBOHYDRATE OR KETOGENIC DIETS, CAN SERVE AS A PREVENTIVE MEASURE AGAINST BREAST CANCER. TUYA PAL, M.D., OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL OFFER AN EDUCATIONAL TOOL FOR GENETIC COUNSELING TO YOUNG AFRICAN AMERICAN WOMEN WITH BREAST CANCER AND EVALUATE OUTCOMES IN GENETIC TESTING ATTITUDES. DR. PAL WILL ALSO EXAMINE BREAST TUMOR SAMPLES AND OUTCOMES FROM AFRICAN AMERICAN AND NON-HISPANIC WHITE WOMEN TO BETTER UNDERSTAND HOW INHERITED MUTATIONS CONTRIBUTE TO DISPARATE BREAST CANCER OUTCOMES. THE GOAL OF THIS PROJECT IS TO BETTER UNDERSTAND HOW GENETIC TESTING FOR INHERITED MUTATIONS IN BREAST CANCER GENES CAN POTENTIALLY REDUCE DISPARITIES IN BREAST CANCER OUTCOMES FOR AFRICAN AMERICAN WOMEN.
OPPORTUNITY GRANTS:	THE TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM (TBCRC), A COLLABORATION OF 19 OF THE TOP U.S. ACADEMIC MEDICAL CENTERS ADMINISTERED OUT OF JOHNS HOPKINS UNIVERSITY, WILL RECEIVE FUNDING, BRINGING KOMEN'S TOTAL INVESTMENT IN THE TBCRC TO $15.5 MILLION. THE TBCRC DEVELOPS AND CONDUCTS INNOVATIVE, HIGH-IMPACT, BIOLOGICALLY-DRIVEN, TRANSLATIONAL RESEARCH PROJECTS AND CLINICAL TRIALS INVESTIGATING NEW TREATMENT APPROACHES FOR BREAST CANCER. LED BY KOMEN SCHOLAR, ANTONIO WOLFF, M.D., THE TBCRC HAS DEVELOPED 57 CLINICAL TRIALS WITH OVER 5,500 PATIENTS ENROLLED. ABOUT HALF OF THESE TRIALS HAVE FOCUSED ON METASTATIC BREAST CANCER, DRUG RESISTANCE AND/OR RECURRENCE SINCE 2006. THE UNIVERSITY OF NORTH CAROLINA WILL RECEIVE FUNDING TO CONTINUE THE CAROLINA BREAST CANCER STUDY (CBCS) TO BETTER UNDERSTAND THE COMPLEX INTERACTIONS OF 'BIOLOGY AND ACCESS' THAT CONTRIBUTE TO DISPARITIES IN BREAST CANCER OUTCOMES. THE CBCS PHASE 3 IS UNIQUELY POSITIONED, ASSEMBLING THE LARGEST DATASET OF BREAST CANCER PATIENTS TO DATE, INCLUDING RURAL WOMEN AND LARGE NUMBERS OF BLACK PARTICIPANTS. THE STUDY WILL COLLECT DETAILED QUALITY OF LIFE AND HEALTH CARE ACCESS INFORMATION, ALONG WITH TUMOR SUBTYPE AND TREATMENT INFORMATION, AND WILL ENABLE RESEARCHERS TO DESIGN NEW INTERVENTIONS THAT IMPROVE SURVIVORSHIP AND QUALITY OF LIFE AMONG PEOPLE WITH BREAST CANCER. YALE UNIVERSITY WILL RECEIVE FUNDING TO BUILD AND PILOT A NEW TOOL TO HELP IMPROVE REPRESENTATION IN CANCER RESEARCH, WITH A FOCUS ON BREAST CANCER. DR. JENNIFER MILLER AND HER TEAM WILL DEVELOP AN INDEX THAT EVALUATES AND RANKS NOVEL CANCER DRUGS AND THEIR DRUG COMPANY SPONSORS. RANKINGS WILL BE BASED ON THE TRANSPARENCY AND REPRESENTATIVENESS OF U.S. PATIENTS IN CLINICAL TRIALS. THIS PROJECT WILL ALSO ENCOURAGE COMPANIES TO BE MORE TRANSPARENT ABOUT DEMOGRAPHICS AND TO ENROLL MORE REPRESENTATIVE PATIENT POPULATIONS TO STUDIES. TRAINING RESEARCHERS TO ELIMINATE DISPARTIES WORKFORCE DEVELOPMENT GRANTS: TRAINING RESEARCHERS TO ELIMINATE DISPARITIES (TREND) GRANTS ARE INTENDED TO ESTABLISH AND/OR TO SUSTAIN AN INNOVATIVE TRAINING PROGRAM FOR GRADUATE STUDENTS, POSTDOCTORAL FELLOWS, OR EARLY CAREER FACULTY MEMBERS WHO ARE SEEKING CAREERS DEDICATED TO UNDERSTANDING AND ELIMINATING DISPARITIES IN BREAST CANCER OUTCOMES ACROSS POPULATION GROUPS. THE TREND PROGRAM PROVIDES CRITICAL FINANCIAL SUPPORT FOR DISPARITIES RESEARCH IN BREAST CANCER THAT OFTEN IS NOT FUNDED. IT IS THE ONLY PROGRAM IN THE U.S. THAT HELPS ESTABLISH AND SUSTAIN BREAST CANCER DISPARITIES RESEARCH TRAINING PROGRAMS BY: (1) ATTRACTING ASPIRING SCIENTISTS INTO RESEARCH CAREERS. (2) PROVIDING THE TOOLS, MENTORSHIP, AND ENVIRONMENT TO TRAIN AND RETAIN SCIENTISTS IN BREAST HEALTH DISPARITIES RESEARCH. (3) EMPOWERING TRAINEES WITH THE SKILLS AND KNOWLEDGE TO TRANSLATE RESEARCH DISCOVERIES INTO CLINICAL AND PUBLIC HEALTH PRACTICE THAT IMPROVES HEALTH EQUITY. THIS YEAR WE FUNDED 3 TREND PROGRAMS. TRAINING RESEARCHERS TO ELIMINATE DISPARITIES (TREND) GRANTS: MARY DOLAN, PH.D., WILL RECEIVE FUNDING TO SUPPORT THE UNIVERSITY OF CHICAGO GRADUATE TRAINING PROGRAM IN BREAST CANCER DISPARITIES. MASTERS AND DOCTORAL STUDENTS WILL LEVERAGE THE INSTITUTION'S STRENGTH IN HEALTH DISPARITIES RESEARCH TO CONDUCT RESEARCH FOCUSED ON UNDERSTANDING AND ELIMINATING BREAST CANCER DISPARITIES. ELECTRA PASKETT, PH.D., OF THE OHIO STATE UNIVERSITY WILL RECEIVE FUNDING TO LEAD THE BREAST CANCER DISPARITIES RESEARCH TRAINING PROGRAM, WHICH WILL OFFER A COMBINATION OF COURSEWORK AND MENTORED RESEARCH FOCUSED ON THE REDUCTION OF BREAST CANCER DISPARITIES TO GRADUATE STUDENTS, POSITIONING THEM FOR A CAREER IN BREAST CANCER DISPARITIES RESEARCH. MELISSA TROESTER, PH.D., M.P.H., OF THE UNIVERSITY OF NORTH CAROLINA, WILL RECEIVE FUNDING TO SUPPORT THE BREAST CANCER MORTALITY DISPARITIES - INTEGRATING BIOLOGY AND ACCESS TRAINING PROGRAM. TRAINEES IN THIS PROGRAM WILL EXPLORE HOW DIFFERENCES IN BIOLOGY, ACCESS TO CARE AND OTHER FACTORS LEAD TO DIFFERENCES IN SURVIVAL BETWEEN BLACK AND WHITE WOMEN WITH BREAST CANCER. EDUCATION KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE "ABOUT BREAST CANCERPORTIONS OF THE "PATIENT & CAREGIVER" SECTIONS OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER CANCER INSTITUTE STAFF, RECEIVED MORE THAN 4 MILLION PAGE VIEWS DURING FY21. KOMEN LAUNCHED THE CLINICAL TRIALS INITIATIVE ON KOMEN.ORG WITH THE GOAL OF HELPING PEOPLE WITH ANY STAGE OF BREAST CANCER FIND AND PARTICIPATE IN CLINICAL TRIALS, INCLUDING THOSE FROM UNDER- REPRESENTED POPULATIONS, INCLUDING TRIALS SUPPORTED BY KOMEN EMPOWERED WITH INFORMATION ON CLINICAL TRIALS AND THROUGH DIRECTING PEOPLE TO THE CLINICAL TRIALS HELPLINE AND OTHER RESOURCES. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACTSHEETS, C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS, AND D) TOOLKITS FOR BREAST CANCER OUTREACH AND EDUCATION FOR HISPANIC/LATINO IN ENGLISH AND SPANISH, FOR BLACK AND AFRICAN AMERICAN COMMUNITIES AND FOR LESBIANS, BISEXUAL WOMEN AND TRANSGENDER AND QUESTIONING/QUEER PEOPLE. IN ADDITION, IN FY21 KOMEN CONTINUED TO SUPPORT THE METASTATIC BREAST CANCER (MBC) COMMUNITY BY HOSTING 29 VIRTUAL EVENTS THROUGH THE MBC IMPACT SERIES. THESE EVENTS PROVIDED PEOPLE LIVING WITH METASTATIC BREAST CANCER AND THEIR LOVED ONES A SAFE, COLLABORATIVE SPACE TO GATHER INFORMATION AND DISCOVER PRACTICAL RESOURCES TO HELP MAKE DECISIONS FOR IMPROVED PHYSICAL AND EMOTIONAL HEALTH.
PATIENT SUPPORT	FY21 MARKED THE CREATION OF THE SUSAN G. KOMEN PATIENT CARE CENTER. THE OVERARCHING GOAL OF OUR PATIENT CARE CENTER OFFERINGS IS TO SAVE LIVES BY ENSURING PATIENTS STAY IN THE BREAST CANCER CONTINUUM OF CARE, OVERCOME BARRIERS AND CHALLENGES TO HIGH-QUALITY BREAST CARE SERVICES, COMPLETE TREATMENT, AND HAVE A HIGH QUALITY OF LIFE AND IMPROVED LONG-TERM OUTCOMES. WE SERVE TENS OF THOUSANDS OF INDIVIDUALS NATIONWIDE AND PROVIDE A SUITE OF ESSENTIAL PATIENT SERVICES, INCLUDING ONE-ON-ONE PERSONAL CONNECTION TO OFFER PSYCHOSOCIAL SUPPORT; RESOURCE NAVIGATION TO LOCAL SERVICES; BREAST HEALTH EDUCATION; CONNECTION TO CLINICAL TRIALS; AND FINANCIAL ASSISTANCE TO PATIENTS IN TREATMENT. THE PATIENT CARE CENTER INCLUDES THE SUSAN G. KOMEN BREAST CARE HELPLINE, THE TREATMENT ASSISTANCE PROGRAM, AND PATIENT NAVIGATION. THE CENTER SERVED OVER 17,000 PEOPLE IN FY21. KOMEN DISPARITIES SUMMIT WE CONVENED THE SECOND ANNUAL SUSAN G. KOMEN BREAST CANCER DISPARITIES SUMMIT TO HEAR FROM LEADERS IN THE FIELD ON THE NEXT STEPS NEEDED IN THIS CRITICAL AREA. BREAST CANCER DISPARITIES EXPERTS, ADVOCATES AND TRAINEES CONVENE TO DISCUSS & IDENTIFY EVIDENCE-BASED SOLUTIONS FOR ACTIONABLE CHANGE THAT ADVANCE HEALTH EQUITY. MBC COLLABORATIVE RESEARCH INITIATIVE KOMEN LAUNCHED THE METASTATIC BREAST CANCER RESEARCH INITIATIVE WITH A PILOT PROGRAM AT DUKE UNIVERSITY AND THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL. THE GOAL IS TO CATALYZE AND SUPPORT MULTI-INSTITUTIONAL RESEARCH COLLABORATIONS AND BRING TOGETHER THE BEST AND BRIGHTEST RESEARCHERS AT SETLECT INSTITUTIONS TO SHARE IDEAS, EXPERTISE AND RESOURCES. KOMEN WILL SUPPORT RESEARCH GRANT TO FIND BREAKTHROUGH DISCOVERIES TO END METASTATIC BREAST CANCER. INFLAMMATORY BREAST CANCER COLLABORATIVE FOR THE FIRST TIME, KOMEN IS LEADING TO DRIVE A NEW DIAGNOSTIC DEFINITION OF BREAST CANCER, SPECIFICALLY INFLAMMATORY BREAST CANCER, A DEADLY AND AGGRESSIVE FORM OF CANCER. KOMEN HAS PARTNERED WITH THE INFLAMMATORY BREAST CANCER RESEARCH FOUNDATION AND THE MILBURN FOUNDATION TO CONVENE PATIENT ADVOCATES, BREAST CANCER RESEARCHERS AND CLINICIANS TO REVIEW THE STATE OF IBC CARE AND RESEARCH GLOBALLY AND PROPOSE SPECIFIC INITIATIVES TO MOVE THE FIELD FORWARD. THE OUTCOME OF THE DISCUSSIONS WAS ABUNDANTLY CLEAR: THE FIELD NEEDS A FORMAL DEFINITION OF IBC. WITHOUT A CLEAR DEFINITION, BOTH PATIENT CARE AND RESEARCH SUFFER. DIAGNOSIS REMAINS SUBJECTIVE AND TREATMENT VARIABLE. THE GOAL IS TO MOVE BEYOND THE SUBJECTIVE 'CLINICAL DIAGNOSIS' TO A SET OF SPECIFIC DIAGNOSTIC CRITERIA AND SCORING SYSTEM THAT WILL ADVANCE IBC RESEARCH AND FACILITATE THE DISCOVERIES THAT WILL IMPROVE CARE OF IBC PATIENTS. A PROPOSED DEFINITION OF IBC, BASED ON A REVIEW OF CLINICAL, AND PATHOLOGIC FEATURES WAS SUBMITTED FOR PUBLICATION. BIG DATA FOR BREAST CANCER KOMEN CONTINUES WORK ON THE BIG DATA FOR BREAST CANCER INITIATIVE, WHICH IS AIMED AT USING BIG DATA TO FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE. KOMEN EMPOWERS BREAST CANCER PATIENTS, ADVOCATES AND THE PUBLIC WITH INFORMATION AND TOOLS TO MAKE DATA SHARING UNDERSTANDABLE THROUGH THE BIG DATA FOR BREAST CANCER PATIENTS EDUCATIONAL PROGRAMS. WE ALSO ADDRESS THE CHALLENGES OF INCORPORATING BIG DATA APPLICATIONS INTO BREAST CANCER RESEARCH AND CLINICAL CARE THROUGH WORKING WITH PARTNERS REPRESENTING A VARIETY OF STAKEHOLDERS IN BREAST CANCER RESEARCH. ADDITIONALLY, KOMEN SUPPORTS DATA SCIENCE PROJECTS TO IMPROVE BREAST CANCER OUTCOMES AND SAVE LIVES. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE NONPARTISAN VOICE OF MORE THAN 3.8 MILLION BREAST CANCER SURVIVORS, THOSE LIVING WITH THE DISEASE AND THE PEOPLE WHO LOVE THEM. KOMEN WORKS TO EDUCATE PEOPLE ABOUT PUBLIC POLICY ISSUES, SO THEY ARE EMPOWERED TO BECOME FORCEFUL ADVOCATES FOR THEMSELVES AND THEIR NEIGHBORS, AND THEN UNITES THEIR COLLECTIVE VOICES FOR MAXIMUM IMPACT. THROUGH OUR CENTER FOR PUBLIC POLICY, KOMEN ENSURES THAT OUR POLICYMAKERS ARE EDUCATED ABOUT THE NEEDS OF BREAST CANCER PATIENTS AND PRIORITIZE THE ISSUES IMPACTING THEM. ONLY THROUGH INFORMED GOVERNMENT ACTION CAN WE MAKE THE BROAD, SYSTEMIC AND LASTING CHANGE REQUIRED. KOMEN'S 2020-2021 PUBLIC POLICY AND ADVOCACY PRIORITIES INCLUDED: EXPANDING ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL PATIENT POPULATIONS; SUPPORTING INCREASED STATE AND FEDERAL FUNDING FOR BREAST CANCER RESEARCH AND INCREASED EDUCATION, UTLIZATION OF AND ACCESS TO CLINICAL TRIALS; SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; AND ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC IMAGING. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR PUBLIC POLICY AND ADVOCACY PRIORITIES, KOMEN ALSO ENGAGED ON ISSUES RELATED TO CUSTOM BREAST PROTHESES, GENETIC AND GENOMIC TESTING, LYMPHEDEMA, MEDICARE WAITING PERIODS, PALLIATIVE CARE, SURPRISE MEDICAL BILLING AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK.
FORM 990, PART VI, LINE 1A	EXECUTIVE COMMITTEE THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES.
FORM 990, PART VI, LINE 11B	DESCRIBE THE PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW 990 MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING.
FORM 990, PART VI, LINE 12C	DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICTS OF INTEREST KOMEN'S CONFLICT OF INTEREST POLICY REQUIRES EVERY BOARD MEMBER, OFFICER, COMMITTEE MEMBER, ADVISORY BOARD MEMBER, AND EMPLOYEE TO AVOID CONFLICTS OF INTEREST. IT ALSO REQUIRES THESE PERSONS TO REPORT ANY ACTUAL AND/OR POTENTIAL CONFLICTS OF INTEREST AS SOON AS POSSIBLE. REPORTS ARE REVIEWED BY THE GENERAL COUNSEL'S OFFICE AND/OR INTERNAL AUDIT, AND APPROPRIATE ACTION IS TAKEN PURSUANT TO THE CONFLICT OF INTEREST POLICY. FURTHER, KOMEN PRODUCES AN ANNUAL SURVEY REQUIRING ALL BOARD MEMBERS, OFFICERS, COMMITTEE MEMBERS, ADVISORY BOARD MEMBERS, AND EMPLOYEES TO REVIEW THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY ADDITIONAL ACTUAL/POTENTIAL CONFLICTS OF INTEREST. THESE ANNUAL DISCLOSURES ARE REVIEWED IN THE SAME MANNER. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS RECEIVES, AND REVIEWS ALL REPORTED ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND THE RELATED ACTION TO ADDRESS THEM.
FORM 990, PART VI, LINE 15A & 15B	OFFICERS & POSITIONS FOR WHICH PROCESS WAS USED & YEAR PROCESS WAS BEGUN THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2019, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.
FORM 990, PART VI, LINE 19	AVAIL OF GOV DOCS, CONFLICT OF INTEREST POLICY & FIN STMTS TO GEN PUBLIC KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 1 For nearly 40 years, Susan G. Komen has worked to fulfill its vision of creating a world without breast cancer through its mission of saving lives by meeting the most critical needs in our communities and investing in breakthrough research to better detect, prevent, treat breast cancers. Over the last year, Komen continued to implement a series of changes begun in 2020 to strengthen its financial and operational position in response to the changing needs of the breast cancer community and economic conditions resulting from the COVID-19 pandemic. Komen has nearly completed the consolidation of all operations of its independent Affiliates into its Headquarters organization, resulting in a single organization. This consolidation is enabling Komen to leverage the combined expertise of its mission leaders to deliver a united mission program, utilizing technology as a key driver to connect to people who need to access care where they are and to help improve the patient experience, as well as resulted in administrative and operational efficiencies. In FY20, as a result of the economic pressures generated from the COVID-19 pandemic, Komen reduced Headquarters staffing by 24% in the first quarter. However, as a result of the organization's consolidation and the transition to provide mission services directly, Komen hired 84 former Affiliate staff for community development and 42 mission staff. We anticipate this transition of Komen's operational structure and mission delivery will result in future staff additions to support local engagement and mission delivery. In addition, Komen will continue to shift community mission spending from grants to third-party organizations to direct mission services and grants to individuals through our Treatment Assistance Program and Patient Care Center. Central to Komen's vision is a steadfast commitment to investing in breakthrough research. Komen remained committed to investing in research focused on its primary focus on metastatic breast cancer and understanding and eliminating disparities in breast cancer outcomes between black and white patients. Despite the economic uncertainty and challenging fundraising environment, Komen awarded $14 million in new research awards. We have invested more than $1 billion in over 2700 research grants and more than 500 clinical trials, which have resulted in more than 680 research discoveries since 2016. While we continue to invest in research into new treatments, Komen supports people who are facing breast cancer today through a growing suite of patient care services, including direct financial assistance through its Treatment Assistance Program, eligible to help pay for expenses that may serve as a barrier to attaining the care needed to survive, such as co-pays, transportation, childcare or rent.
FORM 990, PART XI, LINE 9	OTHER CHANGES TO NET ASSETS RESCINDED GRANTS $410,700 EVENT COST RECLASS $2,991 ---------------------------------- TOTAL $413,691